BACKGROUND: Current guidelines recommend treating hypertension in patients with peripheral artery disease (PAD) to reduce the risk of cardiac events and stroke, but the effect of reducing blood pressure on lower extremity PAD events is largely unknown. We investigated the association of blood pressure with lower extremity PAD events using data from the ALLHAT trial (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial).
G
uidelines recommend treating hypertension in patients with peripheral artery disease (PAD) to reduce cardiac events and stroke. 1 However, lowering blood pressure (BP) could theoretically decrease perfusion to the distal extremities and exacerbate PAD symptoms such as claudication and rest pain, or even promote in situ thrombosis. 2, 3 To date, no randomized clinical trial of BP targets has focused specifically on lower extremity PAD events as the primary outcome of interest, and optimal BP targets for PAD events are unknown. 4 Current evidence on this topic comes largely from observational studies. For example, a recent analysis of 4.2 million relatively healthy adults showed a higher risk for incident PAD with each 20 mm Hg increase in systolic blood pressure (SBP) and 10 mm Hg increase in usual diastolic blood pressure (DBP). 5 However, among patients of older age in that study, these linear associations were flattened and attenuated. In a separate analysis of men at high risk for cardiovascular disease, SBP had no significant association with incident PAD, and higher DBP was associated with a lower risk of incident PAD. 6 That study, and other observational studies in high cardiovascular risk cohorts, as well, was limited by relatively few PAD events. 7, 8 We sought to investigate the association of SBP, DBP, and pulse pressure (PP) with lower extremity PAD events in a large cohort of patients with hypertension and an elevated risk of cardiovascular disease. We conducted an analysis using data from the ALLHAT trial (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial) to address our objectives.
METHODS

Study Cohort
The data for this study are publicly available from the National Heart, Lung, and Blood Institute. ALLHAT was a randomized, double-blind, multicenter clinical trial designed to investigate the effect of different antihypertensive medication classes (chlorthalidone, amlodipine, lisinopril, or doxazosin) on cardiovascular events. 9 From February 1994 to March 2002, ALLHAT recruited patients ≥55 years of age with baseline hypertension (SBP>140 mm Hg or DBP>90 mm Hg) and at least 1 other coronary artery disease risk factor (ie, history of myocardial infarction or stroke, history of coronary artery bypass grafting/angioplasty, diabetes mellitus, high-density lipoprotein <35 mg/dL, left ventricular hypertrophy, or current cigarette smoking). The target SBP was set at <140/90 mm Hg for all participants during the trial. Patients with a history of heart failure, left ventricular ejection fraction <35%, or serum creatinine >2 mg/dL were excluded from recruitment. Because the doxazosin arm was terminated early by the data safety monitoring committee because of an excess of heart failure events, 9 we excluded patients randomly assigned to this arm (n=9067) from the present analysis.
Blood Pressure Measurements
Trained study coordinators measured BP using a mercury sphygmomanometer, after allowing the patient to sit comfortably with feet flat on the floor for 5 minutes. We calculated the baseline BP by taking an average of all available prerandomization BP measurements. At each study visit, 2 BP measurements were taken and averaged, and the averaged BP was recorded as the study visit BP. Study visits were scheduled at 1, 3, 6, 9, and 12 months after randomization, and thereafter every 4 months for the duration of follow-up. We calculated PP by taking the difference between the average SBP and DBP at each study visit.
Lower Extremity PAD Events
The primary outcome for the present analysis was a lower extremity PAD event, defined as a PAD-related hospitalization (with or without a revascularization procedure; documented by hospital discharge summary, procedure sheet, or face sheet), PAD-related procedures (lower extremity bypass, angioplasty, revascularization, or amputation), outpatient PAD medical treatment (as per the attending physician's usual care regimen; documented by check box on end point questionnaire), or PAD-related death (as documented by hospital discharge summaries and death certificates). For patients with multiple events during the study period, the first event was analyzed as the event of interest. Each PAD event was based on clinic investigator reports, and 99% of inpatient events had documentation in the form of a death certificate or hospital discharge summary. We conducted a sensitivity analysis limiting the PAD event definition to PADrelated hospitalization or PAD-related procedures only to align with the secondary outcome definition in the original ALLHAT report.
Clinical Perspective
What Is New?
• In this reanalysis of data from the ALLHAT trial (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial), systolic blood pressure <120 mm Hg and ≥160 mm Hg were associated with significantly higher rates of peripheral artery disease (PAD) events, defined as revascularization, hospitalization, or medical treatment for PAD or PAD-related death.
• Diastolic blood pressure <70 mm Hg and pulse pressure ≥65 mm Hg were also associated with increased rates of PAD events.
What Are the Clinical Implications?
• Given the lower blood pressure targets in recent guidelines, further studies are needed to evaluate optimal blood pressure targets with specific regard to lower extremity PAD events.
• In particular, further investigation is needed to evaluate patients with lower systolic and diastolic blood pressure. We used all available BP values recorded before the PAD event, and analyzed the BP component as a time-varying variable. We used extended Cox proportional hazards regression to calculate the subdistribution hazard ratios for PAD events, with robust standard errors accounting for clustering of BP measurements within subjects, and modeling death as a competing risk. Multivariable models were adjusted for age, sex, race, ethnicity, body mass index, smoking status, history of coronary heart disease, history of myocardial infarction or stroke, history of coronary revascularization, history of atherosclerosis (defined as intermittent claudication, gangrene, ischemic ulcers, carotid stenosis, ankle-arm index <0.9, abdominal aortic aneurysm, or carotid or femoral bruits), history of major ECG changes, type 2 diabetes mellitus, presence of high-density lipoprotein <35 mg/dL, aspirin use, number of antihypertensive medications at enrollment, and study randomization group. Of note, baseline PAD status, which was part of the definition of a history of atherosclerosis, was not documented as a separate condition in the ALLHAT data set. We tested the proportionality assumption using log-log plots and regressing Schoenfeld residuals against time for all covariates and did not note any significant violations. We present results as hazard ratios and 95% CIs.
We evaluated whether age, smoking status, and diabetes mellitus modified the association of the BP component with PAD events by including a multiplicative interaction term in each of the relevant models.
Because different SBP and DBP values can generate similar PP, we conducted an exploratory analysis to create a visual representation of the association of SBP and DBP simultaneously with PAD events. The hazard ratios for PAD events were calculated in comparison with a reference value reflecting the median hazard of patients with SBP 120 to 129 mm Hg and DBP 70 to 79 mm Hg. A density plot of the individual hazard ratios in relation to BP recordings from the trial period was then constructed. We overlaid a similar density plot of the frequency with which individual BP values were observed during the trial ( Figure I in the online-only Data Supplement).
Stata version 15 (Stata Corp) was used for statistical analyses. Findings were considered significant if a P value was <0.05. The study was reviewed by a Stanford University Institutional Review Board, which determined that it did not require further review or informed consent because of the deidentified nature of publicly available data set.
RESULTS
A total of 33 357 patients with hypertension at high risk for cardiovascular disease were included in the analysis. At baseline, the median SBP was 146 mm Hg (interquartile range, 137-155 mm Hg), median DBP was 84 mm Hg (interquartile range, 78-90 mm Hg), and median PP was 61.5 mm Hg (interquartile range, 53.5-70 mm Hg; Figure 1 ). The mean age at baseline was 67.4 years, and 53.1% were men. After a median follow-up of 4.3 years (interquartile range, 3.6-5.3 years) representing 140 418 patient-years, 1489 patients (4.5%) Figure 1 . Blood pressure measurements from baseline through followup. Box and whisker plot of systolic blood pressure (Top), diastolic blood pressure (Middle), and pulse pressure (Bottom) from year 0 (randomization) through follow-up. The line within the box represents the median value, whereas length of the box represents the interquartile range. Whiskers extend to 1.5 times the interquartile range.
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had a lower extremity PAD event and there were 4148 (12.4%) non-PAD-related deaths.
Systolic Blood Pressure
Patients with lower baseline SBP were more often men and had a higher prevalence of smoking and coronary heart disease than patients with higher baseline SBP (Table 1) . We found a higher hazard of lower extremity PAD events with lower and higher categories of SBP ( Figure 2 ). For example, SBP<120 mm Hg was associated with a 26% (CI, 5%-52%; P=0.015) higher adjusted hazard and SBP≥160 mm Hg was associated with a 21% (CI, 0%-48%; P=0.050) higher adjusted hazard of a lower extremity PAD event, in comparison with the reference category of SBP 120 to 129 mm Hg. Having a history of cardiovascular disease or diabetes mellitus was associated with higher rates of PAD events, whereas the randomized treatment group (chlorthalidone, amlodipine, or lisinopril) had no association with PAD events (Table I in the online-only Data Supplement).We found no evidence of significant interaction on the association of SBP with PAD events by patient age, smoking status, or diabetes mellitus (P for interaction=0.65, 0.58, 0.42, respectively).
Diastolic Blood Pressure
Patients with lower baseline DBP were older and had a higher prevalence of smoking and coronary heart disease than patients with higher baseline DBP ( Table 2) . In contrast to the U-shaped association of SBP with lower extremity PAD events, lower DBP was associated with a higher hazard of PAD events ( Figure 2 , Table II in the online-only Data Supplement). For example, DBP<60 
Pulse Pressure
Patients with higher baseline PP were older, were less often men, and had a higher prevalence of diabetes mellitus (Table 3) . We observed higher hazards for lower extremity PAD events at lower and higher PP (Figure 2 , Table III in the online-only Data Supplement). We found no evidence of significant interaction by patient age or smoking status (P for interaction=0.46, 0.81, respectively), but did find a marginally significant interaction by diabetes mellitus (P for interaction=0.04). The association of PP with PAD events was significant for patients without diabetes mellitus, but attenuated for patients with diabetes mellitus (Table IV in the online-only Data Supplement).
Sensitivity Analyses
Results were not materially changed when we repeated our analyses using the more restrictive ALLHAT secondary outcome definition for PAD events (PAD-related hospitalization or procedures) ( Figure II in the onlineonly Data Supplement).
Simultaneous Evaluation of SBP and DBP
We evaluated the association of SBP and DBP simultaneously with lower extremity PAD events using 120 to 129/70 to 79 mm Hg as the reference ( Figure 3A ). For any given SBP, lower DBP was associated with higher hazards for a PAD event ( Figure 3B, rows) , whereas, for any given DBP, higher and lower SBPs correspond with higher hazards for a PAD event (Figure 3B, columns) .
DISCUSSION
In patients with hypertension at high risk for cardiovascular events enrolled in ALLHAT, we found a Ushaped association of SBP with PAD events. Specifically, SBP<120 mm Hg was associated with a 26% higher 
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rate of lower extremity PAD, whereas SBP≥160 mm Hg was associated with a 21% higher rate of lower extremity PAD events (comparison with SBP 120-129 mm Hg). We also found that lower DBP (<70 mm Hg), but not higher DBP, was associated with higher rates of lower extremity PAD events. Correspondingly, lower and higher PP was also associated with higher rates of PAD events. Our results contrast with 2 large cohort studies that showed a linear increase in the risk of incident PAD with higher SBP and DBP, without a higher risk with lower SBP or DBP. 5, 10 Differences in our findings likely stem from the fact that those studies were conducted in relatively healthy cohorts of patients without a history of cardiovascular disease, whereas ALLHAT specifically recruited patients with known hypertension and at least 1 additional cardiovascular risk factor, including prevalent PAD. In addition, the lowest range of DBP investigated in those studies was 65 to 70 mm Hg, whereas our study investigated DBP<60 mm Hg.
Similar to our results showing higher rates of PAD with lower DBP, in a study of 7529 men at high risk for cardiovascular disease enrolled in the MRFIT study (Multiple Risk Factor Intervention Trial), 6 higher DBP was associated with a lower risk of incident PAD (odds ratio, 0.99; P=0.003). Lower DBP is associated with a higher risk of coronary events and death in high risk patients, which has been described as a J-curve association. [11] [12] [13] [14] [15] [16] [17] [18] Our results extend these findings to also include PAD events.
The mixed results depending on the relative health of the cohorts may reflect the fact that lower DBP, and the resultant higher PP, may be a marker for vascular stiffness. Commonly seen in patients at higher risk for cardiovascular events (eg, older patients, patients with (27.6) hypertension, diabetes mellitus, or chronic kidney disease), vascular stiffness is associated with numerous adverse events, including PAD events. [19] [20] [21] [22] [23] The study by Rapsomaniki et al 10 confirms the association between PAD and elevated PP, where higher PP was associated with higher risk of PAD (hazard ratio per 10 mm Hg, 1.23; CI, 1.20-1.27).
Another possible explanation for our observed association between lower DBP and higher rates of PAD events may be attributable to the relative importance of lower extremity perfusion during diastole. In healthy individuals, SBP increases by 50 to 70 mm Hg during exercise, whereas the DBP shows only minor changes; however, in patients with hypertension, DBP increases during exercise to a greater degree because of the inability to adequately reduce peripheral resistance. 24 Therefore, in the setting of PAD, where systolic flows are dampened by atherosclerotic disease in the lower extremities, perfusion becomes more dependent on DBP during exercise. In support of this theory, 1 study showed PAD being the only cardiovascular event that had a lower associated risk at higher mean arterial pressure (hazard ratio per 10 mm Hg, 0.90; CI, 0.86-0.94), which is largely determined by DBP. 10 Finally, because coronary perfusion occurs during diastole, patients with lower DBP may experience exertional angina that limits their exercise capacity, which may in turn increase the risk for a lower extremity PAD event.
It is also possible that intentionally lowering SBP and DBP to reduce the risk of cardiac and stroke events reduces lower extremity perfusion, leading to more PAD events. In SPRINT (Systolic Blood Pressure Intervention Trial), 25 participants randomly assigned to an intensive SBP target of <120 mm Hg (versus a standard SBP target of <140 mm Hg) had a 25% lower rate of 
fatal and nonfatal cardiovascular events, including PAD events; moreover, intensive SBP control was as effective among patients in the lowest quintile of baseline DBP (<68 mm Hg) as in the highest quintile. 26 However, in SPRINT, there were too few PAD events to analyze the effect of intensive SBP control on these outcomes separately. To date, no randomized clinical trial of different BP targets has been powered to examine PAD events specifically.
Some recent studies have demonstrated a higher risk for lower extremity amputation with one of the sodium-glucose cotransporter 2 inhibitors, 27,28 canagliflozin, and although this association requires further confirmation, 1 potential concern is the risk of volume depletion on subsequent PAD events. In the original ALLHAT report, randomization to chlorthalidone, amlodipine, or lisinopril had no significant effect on the occurrence of PAD events. 9 Similarly, in our analysis, we showed no association of randomized treatment group with PAD events when including the various BP components of interest. Piller et al, 29 in a separate post hoc analysis using ALLHAT data, also found no differences in PAD events when comparing chlorthalidone with amlodipine or lisinopril. Future studies are needed to elucidate the most appropriate pharmacotherapy, along with optimal BP levels, to reduce PAD events in high-risk patients.
Our analysis has several strengths. First, in ALLHAT, BP was carefully measured in duplicate according to guideline-recommended protocols. We were also able to leverage longitudinal BP measurements throughout the duration of follow-up. Second, PAD events in ALL-HAT were defined by the treating clinician with hospital discharge summaries and death certificates in 99% of inpatient cases. Finally, given the large size of our relatively high-risk cohort with >140 000 patient-years of follow-up, we were able to capture >1000 PAD events, significantly more than many prior studies.
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Figure 3. PAD event hazard ratios of simultaneous systolic and diastolic blood pressure measurements. A, Models evaluating the association of systolic and diastolic blood pressure simultaneously with the risk of a lower extremity PAD event, reported as hazard ratios (HRs). The reference category is set at 120 to 129/70 to 79 mm Hg (HR, 0.9-1.1) and is shown in white, with higher hazards (>1.1) shown in red and lower hazard (<0.9) shown in blue. The figure is overlaid with a density plot of blood pressure measurement frequency, with darker areas indicating less frequent readings and brighter areas indicating more frequent readings. B, Examples of blood pressure measurements with corresponding HRs for a lower extremity PAD event. BP indicates blood pressure; and PAD, peripheral artery disease. ORIGINAL RESEARCH ARTICLE However, there are also some limitations to our study. First, ALLHAT did not ascertain baseline PAD as a separate comorbid condition, including it instead as part of the other atherosclerosis definition. Although we included this variable in our adjusted models, we could not examine incident versus recurrent PAD events separately. Second, ALLHAT did not capture asymptomatic PAD or the reasons for lower extremity revascularization (eg, claudication versus critical limb ischemia), and we were thus unable to examine the association of BP components with a more granular stratification of lower extremity PAD events. Third, because PAD events were a secondary outcome, the trial did not rigorously confirm these findings in the same manner as the primary outcome of cardiac events. Given the heterogeneity in PAD event definition among different studies, future investigations should include standardized protocols for PAD event ascertainment. [30] [31] [32] Finally, as with any observational study, the associations observed among SBP, DBP, and PP and lower extremity PAD event are not necessarily causal and could still be affected by residual confounding.
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CONCLUSIONS
In this reanalysis of ALLHAT, we show a higher rate of lower extremity PAD events with higher and lower SBP and PP, and with lower DBP. The 2017 American College of Cardiology/American Heart Association blood pressure guidelines advocate a target BP of <130/80 mm Hg for nearly all patients with hypertension for overall cardiovascular risk reduction, 33 and our results suggest that this BP target may not be optimal with regard to lower extremity PAD events. Future studies are needed to refine BP targets for prevention of lower extremity PAD events.
